Trethera and UCLA enter into research collaboration agreement for the development of novel anti-cancer agents

Beverly Hills, CA, 23 March 2016 – Trethera, a biotechnology company focused on the discovery and development of innovative small molecules for the treatment of hematological and solid tumors today announced that they have entered into a collaborative research agreement with the University of California, Los Angeles (UCLA) to develop novel anti-cancer agents.

Under the formal agreement, UCLA and Trethera will undertake collaborative research activities intended to support Trethera’s technology platform which is based on the pharmacologic blockade of DNA synthesis and DNA repair pathways.

Dr. Holldack, CEO of Trethera, said: “We believe that our drug development capabilities combined with the scientific expertise of UCLA’s investigators in cancer biology, will produce a synergistic collaboration purposed to advance new therapeutics into clinical development.”

Read full press release

Trethera attending the 8th Annual Biotech Showcase 2016

Beverly Hills, CA, 4 January 2016 – Trethera, a biotechnology company focused on the discovery and development of innovative small molecules for the treatment of hematological and solid tumors will be attending Biotech Showcase, San Francisco, USA, 11th-13th January 2016. The Company’s targeted metabolic pathway therapy approach involves using a rationally-designed combination of two or three drugs from the very start of cancer treatment.

Trethera Appoints Dr. Johanna Holldack as President & CEO

Beverly Hills, CA, 1 November 2015 – Trethera, a biotechnology company focused on the discovery and development of innovative small molecules for the treatment of hematological and solid tumors today announced the appointment of Dr. Johanna Holldack as President and Chief Executive Officer. The appointment is effective immediately.

Read full press release